Cartesian Therapeutics (RNAC) FCF Margin (2016 - 2025)
Historic FCF Margin for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to 3737.17%.
- Cartesian Therapeutics' FCF Margin fell 58513800.0% to 3737.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 6315.12%, marking a year-over-year decrease of 62141400.0%. This contributed to the annual value of 84.21% for FY2024, which is 1133300.0% up from last year.
- According to the latest figures from Q3 2025, Cartesian Therapeutics' FCF Margin is 3737.17%, which was down 58513800.0% from 6750.34% recorded in Q2 2025.
- Cartesian Therapeutics' FCF Margin's 5-year high stood at 2114.21% during Q3 2024, with a 5-year trough of 6750.34% in Q2 2025.
- Over the past 5 years, Cartesian Therapeutics' median FCF Margin value was 106.02% (recorded in 2021), while the average stood at 582.43%.
- As far as peak fluctuations go, Cartesian Therapeutics' FCF Margin soared by 22548800bps in 2024, and later plummeted by -67003300bps in 2025.
- Over the past 5 years, Cartesian Therapeutics' FCF Margin (Quarter) stood at 106.02% in 2021, then surged by 32bps to 71.81% in 2022, then tumbled by -293bps to 282.48% in 2023, then surged by 459bps to 1015.42% in 2024, then tumbled by -468bps to 3737.17% in 2025.
- Its FCF Margin stands at 3737.17% for Q3 2025, versus 6750.34% for Q2 2025 and 2198.45% for Q1 2025.